BTCP maleate (Benocyclidine HCL) (CAS: 112726-66-6) is a synthetic compound that belongs to the class of phenylcyclohexylamines. It is a potent dissociative anesthetic drug that has been used in veterinary medicine, but it has not been approved for medical use by any regulatory agency. The drug has also gained popularity among recreational drug users due to its dissociative and hallucinogenic effects. However, its use carries significant risks, including potential overdose and long-term mental health problems.
Chemical name
The chemical name for BTCP maleate is 1-(1,2-benzothiazol-3-yl)-N-methylcyclohexanamine maleate.
Molecular formula
The molecular formula for BTCP maleate is C16H21N2O4S.
Formula weight
The formula weight for BTCP maleate is 343.42 g/mol.
CAS No.
The CAS number for BTCP maleate is 112726-66-6.
Top Ten Keywords from Google and Synonyms
Health Benefits of This Product
BTCP maleate has no known health benefits and is not approved for medical use by any regulatory agency. It is classified as a research chemical or novel psychoactive substance and is primarily used for recreational purposes.
Potential Effects
The effects of BTCP maleate on humans are not well understood, as the drug has not been extensively studied in clinical trials. The drug is reported to produce dissociative and hallucinogenic effects similar to other phenylcyclohexylamines, including altered perception of reality, distorted sense of time, and out-of-body experiences. However, there have been reports of adverse effects such as confusion, agitation, and psychosis at higher doses. The onset of effects is rapid, with peak effects occurring within 20-30 minutes of ingestion. The duration of effects can last up to several hours.
Product Mechanism
The mechanism of action of BTCP maleate on humans is not well understood, but it is believed to work by blocking NMDA receptors in the brain. These receptors are responsible for regulating the transmission of signals between neurons, and their blockade leads to a decrease in brain activity and a state of dissociation. By altering sensory perception and inducing a dream-like state, BTCP maleate produces dissociative and hallucinogenic effects.
Safety
As BTCP maleate has not been approved for medical use by any regulatory agency, there is limited information on its safety profile. The drug's potential side effects and long-term effects on the brain are not well understood, and its use carries a high risk of adverse effects.
Side Effects
Common side effects of phenylcyclohexylamine drugs include nausea, vomiting, dizziness, headache, and fatigue. In some cases, these drugs can cause cardiovascular problems such as increased heart rate and blood pressure. At higher doses, users may experience confusion, agitation, and even psychosis. Overdose can lead to severe respiratory depression, seizures, coma, and even death.
Dosing Information
Due to the lack of regulation and standardization, dosing information for BTCP maleate is highly variable and often inaccurate. Users should exercise caution when using this drug and start with small doses to gauge their tolerance. A typical dose of BTCP maleate ranges from 50-150 mg, with a maximum daily dose of 300 mg. However, due to the drug's high potency, even small amounts can cause adverse effects and potential overdose.
Conclusion
BTCP maleate is a synthetic compound that belongs to the class of phenylcyclohexylamines. The drug has been used in veterinary medicine as a dissociative anesthetic agent, but it has not been approved for medical use by any regulatory agency. The drug's safety and efficacy in humans are not well understood, and its use as a research chemical or experimental drug carries a high risk of adverse effects. Therefore, it is essential to exercise caution when using this drug and seek professional help if experiencing adverse effects or symptoms of overdose. Further research is needed to determine the safety and efficacy of BTCP maleate in humans.
